Can Eli Lilly Stock Reach $2,100? A Look at the Upside

Can Eli Lilly Stock Reach $2,100? A Look at the Upside

According to an analysis from Trefis, Eli Lilly (LLY) at $1,189 appears set for roughly 76% upside over the next three years under a conservative scenario. This potential move is significant enough to warrant a deeper look into its drivers.

Revenue Compounding as the Engine

The analysis assumes that revenue compounding will be the primary driver of stock appreciation. However, the valuation multiple (e.g., price-to-earnings) is expected to decline meaningfully over the period, reducing the total return.

The Operational Reality

The math is built on specific operational assumptions:

• Continued strong sales growth from key drugs like Mounjaro and Zepbound.
• Expanding profit margins due to economies of scale.
• Effective cost management.

What This Means for Investors

The analysis presents an optimistic yet conservative scenario, acknowledging that current valuation multiples may not persist. Investors should monitor the company's ability to deliver revenue growth and manage market expectations regarding multiples.